GLP-1 Receptor Agonists: From Semaglutide to Retatrutide

GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic the action of glucagon-like peptide-1, a naturally occurring incretin hormone. When you eat, your gut releases GLP-1, which signals the pancreas to produce insulin, tells the brain you are full, and slows gastric emptying so food is digested more slowly.

Natural GLP-1 has a half-life of only 2-3 minutes — it is rapidly degraded by an enzyme called DPP-4. The breakthrough behind modern GLP-1 drugs was engineering modified versions of this peptide that resist enzymatic degradation, extending the half-life from minutes to days or even a week.

GLP-1 RAs have become one of the most significant drug classes in modern medicine, transforming the treatment of type 2 diabetes and obesity. The global market for GLP-1 drugs exceeds $50 billion annually, driven primarily by semaglutide and tirzepatide.

GLP-1 receptor agonists work through multiple mechanisms simultaneously:

Appetite regulation. GLP-1 receptors are present in brain regions that control hunger and satiety, particularly the hypothalamus and brainstem. Activation of these receptors reduces appetite and increases feelings of fullness. This central mechanism is responsible for much of the weight loss effect.

Insulin secretion. GLP-1 RAs stimulate glucose-dependent insulin secretion from pancreatic beta cells. The glucose-dependent aspect is important — insulin is released primarily when blood sugar is elevated, reducing the risk of hypoglycemia (dangerously low blood sugar) compared to some other diabetes medications.

Gastric emptying. GLP-1 RAs slow the rate at which food leaves the stomach, contributing to prolonged feelings of fullness after meals. This also helps reduce post-meal blood glucose spikes.

Glucagon suppression. GLP-1 RAs reduce secretion of glucagon, a hormone that raises blood sugar by stimulating the liver to release stored glucose. This further improves glycemic control.

The net effect is reduced caloric intake (people eat less because they feel full sooner and longer), improved blood sugar control, and sustained weight loss. Newer dual and triple agonists (tirzepatide, retatrutide) add GIP and glucagon receptor activation for potentially enhanced effects.